Novel CD20 monoclonal antibodies for lymphoma therapy

被引：101

作者：

Cang, Shundong

Mukhi, Nikhil ^{[1
,2
]}

Wang, Kemeng ^{[1
,2
]}

Liu, Delong ^{[1
,2
]}

机构：

[1] New York Med Coll, Dept Med, Valhalla, NY 10595 USA

[2] Westchester Cty Med Ctr, Valhalla, NY 10595 USA

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2012年 / 5卷

关键词：

B-CELL LYMPHOMA; HISTONE DEACETYLASE INHIBITORS; CHEMOTHERAPY PLUS RITUXIMAB; BRENTUXIMAB VEDOTIN SGN-35; CHOP-LIKE CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; PHASE-II TRIAL; INOTUZUMAB OZOGAMICIN; ANTI-CD20; ANTIBODY; MAMMALIAN TARGET;

D O I：

10.1186/1756-8722-5-64

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin's lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab).

引用

收藏

页数：9

相关论文

共 116 条

[1]

Adams J, 1999, CANCER RES, V59, P2615

[2]

Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma [J].

Al-Katib, Ayad M. ;

Aboukameel, Amro ;

Mohammad, Ramzi ;

Bissery, Marie-Christine ;

Zuany-Amorim, Claudia .

CLINICAL CANCER RESEARCH, 2009, 15 (12) :4038-4045

[3]

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies [J].

Alduaij, Waleed ;

Ivanov, Andrei ;

Honeychurch, Jamie ;

Cheadle, Eleanor J. ;

Potluri, Sandeep ;

Lim, Sean H. ;

Shimada, Kazuyuki ;

Chan, Claude H. T. ;

Tutt, Alison ;

Beers, Stephen A. ;

Glennie, Martin J. ;

Cragg, Mark S. ;

Illidge, Tim M. .

BLOOD, 2011, 117 (17) :4519-4529

[4]

The future of anti-CD20 monoclonal antibodies: are we making progress? [J].

Alduaij, Waleed ;

Illidge, Tim M. .

BLOOD, 2011, 117 (11) :2993-3001

[5]

Exploiting the mammalian target of rapamycin pathway in hematologic malignancies [J].

Altman, Jessica K. ;

Platanias, Leonidas C. .

CURRENT OPINION IN HEMATOLOGY, 2008, 15 (02) :88-94

[6]

Baig NA, 2012, LEUK LYMPHOMA

[7]

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma [J].

Barth, Matthew J. ;

Hernandez-Ilizaliturri, Francisco J. ;

Mavis, Cory ;

Tsai, Ping-Chiao ;

Gibbs, John F. ;

Deeb, George ;

Czuczman, Myron S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (04) :490-498

[8]

Histone deacetylase inhibitors as anti-neoplastic agents [J].

Batty, Nicolas ;

Malouf, Gabriel G. ;

Issa, Jean Pierre J. .

CANCER LETTERS, 2009, 280 (02) :192-200

[9]

A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150 [J].

Belch, A. ;

Kouroukis, C. T. ;

Crump, M. ;

Sehn, L. ;

Gascoyne, R. D. ;

Klasa, R. ;

Powers, J. ;

Wright, J. ;

Eisenhauer, E. A. .

ANNALS OF ONCOLOGY, 2007, 18 (01) :116-121

[10]

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion [J].

Biberacher, Viola ;

Decker, Thomas ;

Oelsner, Madlen ;

Wagner, Michaela ;

Bogner, Christian ;

Schmidt, Burkhard ;

Kreitman, Robert J. ;

Peschel, Christian ;

Pastan, Ira ;

zum Bueschenfelde, Christian Meyer ;

Ringshausen, Ingo .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (05) :771-779

← 1 2 3 4 5 6 7 8 9 10 →